Haleon plc
General ticker "HLNCF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $43.1B (TTM average)
Haleon plc does not follow the US Stock Market performance with the rate: -13.9%.
Estimated limits based on current volatility of 1.3%: low 4.55$, high 4.67$
Factors to consider:
- Company pays dividends (semi-annually): last record date 2026-08-14, amount 0.03$ (Y1.30%)
- Total employees count: 10346 (-59.3%) as of 2024
- Price in estimated range
- Earnings for 18 months up through Q2 (+1 year) exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.29$, 6.74$]
- 2025-12-31 to 2026-12-31 estimated range: [4.55$, 7.13$]
Financial Metrics affecting the HLNCF estimates:
- Positive: with PPE of 13.4 at the end of fiscal year the price was neutral
- Positive: 15.80 < Operating profit margin, % of 19.64
- Positive: 42.26 < Shareholder equity ratio, % of 47.11 <= 49.86
- Positive: 4.90 < Operating cash flow per share per price, % of 6.73
- Positive: 3.48 < Return on assets ratio (scaled to [-100,100]) of 4.12
- Positive: Inventory ratio change, % of -1.50 <= -1.30
- Positive: -0.14 < Investing cash flow per share per price, % of 1.54
- Positive: -6.44 < Industry operating cash flow per share per price (median), % of -3.22
- Positive: -51.61 < Industry operating profit margin (median), % of -23.39
Short-term HLNCF quotes
Long-term HLNCF plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | £11,302.00MM | £11,233.00MM | £11,028.21MM |
| Operating Expenses | £9,306.00MM | £9,027.00MM | £8,444.63MM |
| Operating Income | £1,996.00MM | £2,206.00MM | £2,583.58MM |
| Non-Operating Income | £-368.00MM | £-296.00MM | £-431.93MM |
| Interest Expense | £414.00MM | £394.00MM | £339.94MM |
| R&D Expense | £311.00MM | £298.00MM | £314.95MM |
| Income(Loss) | £1,628.00MM | £1,910.00MM | £2,151.65MM |
| Taxes | £517.00MM | £435.00MM | £471.92MM |
| Net Income(Loss)* | £1,049.00MM | £1,442.00MM | £1,666.73MM |
| Stockholders Equity | £16,606.00MM | £16,166.00MM | £16,422.34MM |
| Inventory | £1,408.00MM | £1,190.00MM | £1,024.83MM |
| Assets | £34,055.00MM | £34,315.00MM | £32,624.71MM |
| Operating Cash Flow | £2,100.00MM | £2,301.00MM | £2,336.62MM |
| Capital expenditure | £336.00MM | £318.00MM | £321.95MM |
| Investing Cash Flow | £-134.00MM | £528.00MM | £-579.91MM |
| Financing Cash Flow | £-1,568.00MM | £-1,537.00MM | £-2,611.58MM |
| Earnings Per Share** | £0.11 | £0.16 | £0.19 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.